The UK’s national healthcare provider saved £324 million by switching its patients to “better value” biosimilar and generic drugs, which are considered to be “equally effective alternatives
European Commission (EC) has approved Pfizer’s Trazimera, for breast and gastric cancer treatment, marking it as pharma’s first oncology biosimilar to receive approval in the EU.
Gilead may be looking for a deal-broker who can kick-start the company’s growth after the lacklustre launch of its CAR-T therapy, after CEO John Milligan announced he is to step down at the
